805 Oncolytic adenovirus encoding human interleukin-7 in combination with ICIs as a treatment strategy against renal cell carcinoma (RCC)

805 Oncolytic adenovirus encoding human interleukin-7 in combination with ICIs as a treatment strategy against renal cell carcinoma (RCC)

Bibliographic Details
Main Authors:	Akseli Hemminki, Víctor Cervera-Carrascón, Otto Hemminki, João Manuel Santos, Saru Basnet, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Susanna AM Grönberg-Vähä-Koskela, Victor Arias
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
by: Santeri Pakola, et al.
Published: (2023-07-01)

806 Oncolytic adenovirus coding for human Mucin1 T cell engager with interleukin-2 potentiates anti-tumor T cell responses against tumors
by: Akseli Hemminki, et al.
Published: (2023-11-01)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
by: James H. A. Clubb, et al.
Published: (2023-02-01)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
by: Saru Basnet, et al.
Published: (2023-03-01)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
by: Camilla Heiniö, et al.
Published: (2022-08-01)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
by: Joao Santos, et al.
Published: (2021-04-01)

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
by: Dafne C. A. Quixabeira, et al.
Published: (2022-12-01)

739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
by: Tuomo Alanko, et al.
Published: (2023-11-01)

814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade
by: Akseli Hemminki, et al.
Published: (2023-11-01)

745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123)
by: Tuomo Alanko, et al.
Published: (2023-11-01)

711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials
by: Tuomo Alanko, et al.
Published: (2023-11-01)

1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
by: Tuomo Alanko, et al.
Published: (2023-11-01)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
by: Tatiana V. Kudling, et al.
Published: (2022-12-01)

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
by: Tuomo Alanko, et al.
Published: (2025-01-01)

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors
by: Elise Jirovec, et al.
Published: (2024-11-01)

749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
by: Marco Donia, et al.
Published: (2023-11-01)

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
by: Matthew Stephen Block, et al.
Published: (2025-02-01)

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
by: Tatiana V. Kudling, et al.
Published: (2023-12-01)

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
by: Siri Tähtinen, et al.
Published: (2015-01-01)

Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
by: Matti Kankainen, et al.
Published: (2022-02-01)

Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma
by: T.J. Monberg, et al.
Published: (2024-12-01)

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
by: Camilla Heiniö, et al.
Published: (2020-03-01)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
by: Akseli Hemminki, et al.
Published: (2020-05-01)

Oncolytic Immunotherapy: Where Are We Clinically?
by: Akseli Hemminki
Published: (2014-01-01)

Portrait of a Leader in Immunotherapeutics<subtitle>Oncolytic viruses for treatment of cancer</subtitle>
by: Akseli Hemminki
Published: (2012-08-01)

TILT Biotherapeutics
by: Akseli Hemminki
Published: (2017-05-01)

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
by: Riikka Havunen, et al.
Published: (2021-01-01)

Survival in colon and rectal cancers in Finland and Sweden through 50 years
by: Akseli Hemminki, et al.
Published: (2021-10-01)

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
by: Victor Cervera-Carrascon, et al.
Published: (2020-06-01)

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.
by: Kari Hemminki, et al.
Published: (2022-01-01)

High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers
by: Kari Hemminki, et al.
Published: (2025-02-01)

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries
by: Filip Tichanek, et al.
Published: (2023-01-01)

Survival in gastric and esophageal cancers in the Nordic countries through a half century
by: Kari Hemminki, et al.
Published: (2023-05-01)

Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries
by: Kari Hemminki, et al.
Published: (2022-12-01)

Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers
by: Kari Hemminki, et al.
Published: (2025-02-01)

Conditional survival in breast cancer up to 10 years in the Nordic countries
by: Frantisek Zitricky, et al.
Published: (2023-09-01)

Oncolytic viruses for cancer immunotherapy
by: Otto Hemminki, et al.
Published: (2020-06-01)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
by: Kari Hemminki, et al.
Published: (2022-04-01)

Oncolytic adenovirus for treatment of malignant ascites
by: Akseli Hemminki, et al.
Published: (2022-09-01)

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients
by: Kari Hemminki, et al.
Published: (2024-08-01)